DrugBiological
Dezamizumab clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
3 studies that test it; most in 2013 (1)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2017 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses dezamizumab is read from its arms, and is right about nine times in ten.
Testing it · 3
- Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698TerminatedPhase 2GlaxoSmithKlineNCT03044353Written as GSK2398852 (anti-SAP mAb)
- Biodistribution of 89Zirconium-labelled GSK2398852 Using PET ImagingTerminatedPhase 1GlaxoSmithKlineNCT03417830Written as GSK2398852 (unlabeled anti-SAP mAb)
- A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic AmyloidosisCompletedPhase 1GlaxoSmithKlineNCT01777243Written as GSK2398852
Codes
What other systems call dezamizumab · ClinicalTrials.gg INT001943
- UNII (FDA) 6U3F28IT58DEZAMIZUMABOne source FDA
- NCI Thesaurus C153210DezamizumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 6U3F28IT58 | DEZAMIZUMAB | One source FDA |
| NCI Thesaurus | C153210 | Dezamizumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.